Mesothelioma laboratory tests
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Overview
Laboratory findings consistent with the diagnosis of mesothelioma include abnormal pleural fluid analysis (decreased pH and pleural fluid/serum glucose ratio). The presence of serum biomarkers such as soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) is suggestive of malignant mesothelioma. Additional laboratory tests include immunophenotypic analysis to identify cell lines of mesothelioma.
Laboratory Findings
Laboratory Findings
Pleural Fluid Analysis
- Pleural fluid analysis, via thoracentesis, may be performed to help in the diagnosis of pleural mesothelioma.[1]
- Pleural mesothelioma is associated with decreased pleural pH (< 7.30) and decreased pleural fluid/serum glucose ratios.
- Pleural fluid cytology may or may not be positive for mesothelioma.[2]
Serum Biomarker
The presence of serum biomarkers such as soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) is suggestive of malignant mesothelioma.[3]
Immunophenotypic analysis
- All cell lines of mesothelioma express surface human leukocyte antigen (HLA) class I and intercellular adhesion molecule-1 (ICAM-1).[4]
- Chromosome-6 abnormalities are commonly found in with mesothelioma cell lines with abnormal karyotypes.
- In addition these cell lines on immunophenotypic analysis may show:
- Vimentin
- Cytokeratin 8
- Cytokeratin 18
- Mesothelial antigen recognized by HBME-1 monoclonal antibody
Fluorescence In Situ Hybridization (FISH)
- FISH may be helpful in the diagnosis of mesothelioma. It helps in distinguishing malignant mesothelioma from reactive mesothelial cells in effusions.[5]
- Mutlitarget FISH assay may be used to detect chromosomal abberations (chromosomes 3, 7, 17, and 9p21).
- FISH technique may also be used to explore the alternative mechanism of tumor suppressor gene inactivation by methylation of p16, p14, and p15 gene in the pathogenesis of mesothelioma.[5]
References
References
- ↑ Gottehrer A, Taryle DA, Reed CE, Sahn SA (1991). “Pleural fluid analysis in malignant mesothelioma. Prognostic implications”. Chest. 100 (4): 1003–6. PMID 1914546.
- ↑ Na MJ (2014). “Diagnostic tools of pleural effusion”. Tuberc Respir Dis (Seoul). 76 (5): 199–210. doi:10.4046/trd.2014.76.5.199. PMC 4050067. PMID 24920946.
- ↑ Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, Mutti L (March 1999). “Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis”. Eur. Respir. J. 13 (3): 527–34. PMID 10232421.
- ↑ Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP (March 2010). “Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma”. Am. J. Respir. Crit. Care Med. 181 (6): 620–5. doi:10.1164/rccm.200907-1020OC. PMID 20075387.
- ↑ 5.0 5.1 Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B; et al. (2010). “Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology”. Chest. 138 (1): 137–44. doi:10.1378/chest.09-1951. PMID 20139227.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH